Engineering Processing Properties of Acetaminophen by Cosolvent Screening - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Engineering Processing Properties of Acetaminophen by Cosolvent Screening
The authors used common solvents to develop an initial solvent-screening method for laboratory-scale research to determine the solubility, polymorphism, and crystal properties of various active ingredients.

Pharmaceutical Technology
Volume 34, Issue 8, pp. 61-68

Figure 2: Optical micrographs of crystal habit of acetaminophen Form I crystals grown by cooling in (a) tetrahydrofuran and acetone, (b) methyl ethyl ketone and 1,4-dioxane, (c) nitrobenzene + N-butyl alcohol, and (d) tetrahydrofuran and acetonitrile (scale bar = 500 μm).
Crystal habits of acetaminophen were classified into four typical shapes of prismatic, rhombohedral, hexagonal, and needle with sizes ranging from 50 μm in the cosolvent system of THF and acetone (see Figure 2a) to 4.5 mm in the cosolvent system of MEK and 1,4-dioxane (see Figure 2b) and aspect ratios, defined as length divided by breadth, ranging from 1.07 in the cosolvent system of nitrobenzene and N-butyl alcohol (see Figure 2c) to 7.33 in the cosolvent system of THF and acetonitrile (see Figure 2d) (20). The composition of solvents is known to influence nucleation and growth rates (21). Because THF, acetone, nitrobenzene, 1,4-dioxane, and MEK are hydrogen-bond accepting solvents, they might have preferentially adsorbed at specific faces, thus inhibiting the growth of acetaminophen crystals, or have similar structures to acetaminophen, thus hindering the regular deposition of oncoming molecular layers (22).

Figure 3: A typical differential scanning calorimetry scan of acetaminophen Form I crystals grown in nitrobenzene and N,N-dimethylformamide cosolvent systems.
All acetaminophen crystals harvested from the 88 cosolvent systems exhibited the same typical DSC melting endotherm of about 171 C for Form I acetaminophen as shown in Figure 3. No other polymorph was observed, even though a change in the morphology to a needle shape could be a strong indication of the presence of acetaminophen Form II crystals (14). This important case serves as a reminder that a definitive identification of polymorphism must be based on spectroscopy, X-ray diffraction, or thermal analysis, and not on microscopy alone (7).

The percent of crystallinity of acetaminophen crystals was quantified by dividing the area of a sample melting endotherm by the largest area of melting endotherm of all samples, which turned out to be the acetaminophen crystals grown in the cosolvent system of nitrobenzene and DMF with the enthalpy of melting, ΔH m, of 195.24 J/g (see Table II). The authors suggest two possible reasons that this particular sample had the highest crystallinity. First, the slope of the solubility curve was not steep, so that cooling recrystallization took place gradually. Second, the molecular structures of nitrobenzene and DMF were similar to that of acetaminophen, which might have slowed down the nucleation and growth rate of acetaminophen crystals to yield high-quality crystals (22).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here